Mometasone Furoate Use Around the Eyes: Risks and Alternatives

Introduction to Periocular Corticosteroid Use

The American Academy of Dermatology guidelines warn that increased intraocular pressure, glaucoma, and cataracts have been reported with use of mometasone furoate around the eye, which can result in permanent vision loss 1

Long-term topical corticosteroid use near the eyes requires consideration of regular ophthalmic monitoring, though the American Academy of Otolaryngology notes that long-term intranasal steroid use has not been shown to increase risk of lens opacity or elevated intraocular pressure 2
The distinction between intranasal use and direct periocular application is critical, as drug concentration and ocular exposure are substantially higher in the latter case 2
The face and periocular area are classified as steroid-sensitive sites where local cutaneous side effects occur more frequently, according to the American Academy of Dermatology 1
The periocular skin is particularly thin and has enhanced corticosteroid absorption compared to other body sites 1

High-potency topical corticosteroids, including topical clobetasol propionate, have been used for periocular infantile hemangiomas with good efficacy and no significant adverse effects in initial reports, under ophthalmologic supervision 3
Topical corticosteroids are used to reduce intraocular and corneal inflammation, but intraocular pressure and cataract formation must be monitored with long-term use 4
Lower potency corticosteroids may be considered with extreme caution and ophthalmologic consultation for inflammatory dermatologic conditions near the eyes 1
Non-steroidal alternatives such as tacrolimus or pimecrolimus (calcineurin inhibitors) may be safer options for periocular inflammatory conditions, though these also require careful consideration 1
Emollients alone should be tried first for mild conditions 5

Regular ophthalmic examinations to monitor for increased intraocular pressure, glaucoma, and cataracts are essential if periocular corticosteroid use is unavoidable 1
Treatment duration should be minimized (typically 2-4 weeks maximum for high-potency agents) 1

The American Academy of Dermatology classifies mometasone furoate 0.1% as a high-potency topical corticosteroid (Class III), corresponding to the "potent" category in the European classification 6, 7, 8, 9
This classification places it among corticosteroids with superior potency compared to medium-potency preparations (Class IV-V) but inferior to super-potent ones (Class I) 6

The American Academy of Dermatology does not include desametasone dipropionato in its official classifications of topical corticosteroids 6, 7, 8, 9
This suggests it is not a commonly used or approved topical dermatological preparation in Europe or the United States 9
There may be confusion with betametasone dipropionato, a well-classified and widely used topical corticosteroid available in various formulations and potencies 6, 7, 8, 9

The American Academy of Dermatology recommends avoiding application of mometasone furoate on the face, intertriginous areas, and zones susceptible to steroid atrophy 10
Reevaluation after 2-4 weeks is necessary to determine the need to continue treatment 10
For plaque psoriasis, mometasone furoate can be used for up to 4 weeks 10
For maintenance therapy, intermittent use (2 times/week) can reduce flare-ups 10